Jianxin Chen, ZhenGe Biotech chairman and CEO
January 11, 2022 10:33 AM EST
Financing
Manufacturing

Low-pro­file Shang­hai-based CD­MO se­cures high pro­file in­vestors for 9-dig­it Se­ries C

Paul Schloesser

Associate Editor

In a bid to ex­pand R&D and man­u­fac­tur­ing ca­pa­bil­i­ties, Shang­hai-based ZhenGe Biotech net­ted a $100 mil­lion Se­ries C Tues­day.

With of­fices in Shang­hai and the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Im­munol­o­gy biotech In­ma­gene to join Nas­daq through re­verse merg­er with what's left of Ike­na

A service from the Financial Times